摘要
目的:探讨糖皮质激素联合氨溴索治疗新生儿肺透明膜病(HMD)的临床效果。方法:将2008年1月～2010年1月在本院出生的早产儿60例随机分为观察组和对照组,在综合治疗的基础上两组产前均给予糖皮质激素治疗,观察组产后同时给予氨溴索治疗,评估两组的预防效果。结果:观察组HMD发生率为3.33%,对照组HMD发生率为26.67%,两组比较,差异有统计学意义(P<0.05)。观察组死亡率为0,对照组为10.00%,两组比较,差异无统计学意义(P>0.05)。两组早产儿均未见明显的药物不良反应。结论:糖皮质激素联合氨溴索预防新生儿肺透明膜病的临床效果明确,且无毒副作用,值得应用。
Objective： To investigate the effect about glucocorticoid combined with mucosolvan in treating hyaline membrane disease of newborn. Methods： The 60 cases with premature infants in our hospital from January 2008 to January 2010 were divided into the observe group and the control group. The two groups received the treatment of glucocorticoid before antepartum and the observe group received the treatment of mucosolvan after postpartum at the same time. Results： The incidence rate of HMD was 3.33% in the observe group and was 26.67% in control group ,and there was significant difference in them （P0.05）. The death rate was 0 in the observe group and was 10.00% in control group,and there was no significant difference in them （P0.05）. There was no significant difference in the two groups. Conclusion： The effect about glucocorticoid combined with mucosolvan in treating hyaline membrane disease of newborn is obvious and the side reaction is few,so they are worth being used.
出处
《中国当代医药》
2010年第20期45-46,共2页
China Modern Medicine
关键词
糖皮质激素
氨溴索
新生儿肺透明膜病
Glucocorticoid
Mucosolvan
Hyaline membrane disease of newborn
